Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Abstract

Purpose Foregut carcinoid tumours have a different embryological origin than other gastroenteropancreatic neuroendocrine tumours (GEP NETs). In the total group of GEP NETs (n=131), treatment with 177 Lu-octreotate resulted in tumour remission in 47% of patients, with a median time to progression (TTP) of >36 months. As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin. Methods Nine patients with bronchial, five with gastric and two with thymic carcinoids were treated. All patients had metastasised disease. The intended cumulative dose of 177 Lu-octreotate was 22.2-29.6 GBq. Southwest Oncology Group criteria were used for response evaluation.

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia

“…PRRT has been successfully integrated into the therapeutic algorithm of neuroendocrine tumors (NETs). 45 It usually involves the diagnostic imaging of the receptor to ensure target expression, followed by the application of a therapeutically labeled peptide (e.g. Lutetium-177 octreotate), thus constituting a theranostic procedure.…”

Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids

“…represents an alternative and valuable treatment in neuroendocrine tumor (NET) patients (Kwekkeboom et al 2011), to cause tumor response or stabilization (van Essen et al 2007a). However, NET patients with negative or low-level uptake in SSTR scintigraphy are not optimal candidates for using SSAs as diagnostic or therapeutic tools (van Essen et al 2007b).…”

“…Somatostatin analog (SSA) biotherapy has been shown mainly to control symptoms and improve long-term survival of LC patients, especially those with metastatic ACs (Filosso et al 2002b). Moreover, peptide receptor radionuclide therapy with radiolabeled SSAs, such as [ 177 Lu-DOTA 0 ,Tyr 3 ]-octreotate (van Essen et al 2007a),…”

Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs)

“…SPECT-CT studies with 99m Tc-EDDA/HYNIC-TOC resulted in exact pre-surgical and pre-treatment N/M staging of bronchial and thymic NETs, except in one case where total massive bilateral suprarenal metastatic lesions were detected only on the CT part of SPECT-CT images without tracer uptake and in two cases with negative multiple hepatic lesions. These results were described as false negative, probably due to necrotic process and metastatic cell dedifferentiation with Original absence of somatostatin-receptor expression [10][11][12][13][14][15][16][17][18][19][20][21][22]. Positive imaging results concerning benign thyroid adenoma and suprarenal adenoma could be explained with moderate somatostatin-receptor expression, described in some benign tumors and inflammation [10,22,23].…”

“…A high incidence and density of somatostatin receptors (SSTR2, SSTR3, and SSTR5) are found in thoracic NETs [9,10]. Several somatostatin analogs with high affinity to these receptors have been developed for diagnosis and Original therapy [11][12][13][14][15][16][17]. According to the ENETS recommendations 2015, the functional hybrid PET-CT and SPECT-CT imaging modalities with radiolabeled somatostatin analogs has important role in diagnosis, staging and follow up of patients with bronchial and mediastinal NETs, since these methods are more specific than conventional imaging techniques especially for typical and atypical carcinoids [2]; somatostatin-receptor SPECT-CT/PET-CT studies can also predict the response to peptide receptor radionuclide therapy (PRRT) [1,2].…”